Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 25, Issue 12, 2012, Pages 2651-2657

  Moore, Andreea G ^a   Young, Heather ^b   Keller, Jennifer M ^a   Ojo, Linda R ^a   Yan, Jing ^c   Simas, Tiffany A Moore ^c   Maynard, Sharon E ^d  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Angiogenic factors; Placental growth factor; Preeclampsia; SFlt1; Soluble endoglin

Indexed keywords

ANGIOGENIC FACTOR; ENDOGLIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLOOD SAMPLING; BRAIN HEMORRHAGE; COHORT ANALYSIS; EMERGENCY HEALTH SERVICE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS DEATH; GESTATION PERIOD; HEMOLYSIS; HUMAN; LUNG EDEMA; MAJOR CLINICAL STUDY; MATERNAL DISEASE; MATERNAL MORTALITY; NEWBORN; NEWBORN DEATH; NEWBORN DISEASE; NEWBORN INTENSIVE CARE; OLIGURIA; PREECLAMPSIA; PREMATURE LABOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEIZURE; SOLUTIO PLACENTAE; THROMBOCYTOPENIA;

ADULT; ANGIOGENIC PROTEINS; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PROGNOSIS; PUERPERAL DISORDERS; TRIAGE;

EID: 84870382987     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2012.713055     Document Type: Article

References (30)

1. WHO. World Health Report: Make every mother and child count. Geneva Sibai 2005.
2. Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990;163:1049-54; discussion 1054.
3. Schiff E, Friedman SA, Kao L, Sibai BM. The importance of urinary protein excretion during conservative management of severe preeclampsia. Am J Obstet Gynecol 1996;175:1313-1316. (Pubitemid 26398997)
4. Menzies J, Magee LA, Macnab YC, Ansermino JM, Li J, Douglas MJ, Gruslin A, et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy 2007;26:447-462. (Pubitemid 350232904)
5. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658. (Pubitemid 36278583)
6. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-649. (Pubitemid 43865232)
7. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-683. (Pubitemid 38364626)
8. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, et al.; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005. (Pubitemid 44343543)
9. Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, Mol BW, Pajkrt E. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. Br J Obstet Gynaecol 2012;119(7):778-87.
10. Sibai BM, Lindheimer M, Hauth J, Caritis S, VanDorsten P, Klebanoff M, MacPherson C, et al. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998;339:667-671.
11. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002;77:67-75.
12. Maynard SE, Moore Simas TA, Bur L, Crawford SL, Solitro MJ, Meyer BA. Soluble endoglin for the prediction of preeclampsia in a high risk cohort. Hypertens Pregnancy 2010;29:330-341.
13. Maynard SE, Moore Simas TA, Solitro MJ, Rajan A, Crawford S, Soderland P, Meyer BA. Circulating angiogenic factors in singleton vs multiple-gestation pregnancies. Am J Obstet Gynecol 2008;198(2):200. e1-7 .
14. Bdolah Y, Lam C, Rajakumar A, et al. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? Am J Obstet Gynecol 2008; 198: 428, e421-426.
15. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and smallfor- gestational age. J Matern Fetal Neonatal Med 2008;21:279-287. (Pubitemid 351652513)
16. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021-1038.
17. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9-23.
18. Mijal RS, Holzman CB, Rana S, Karumanchi SA, Wang J, Sikorskii A. Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. J Matern Fetal Neonatal Med 2012;25(7):1135-41.
19. Wang A, Holston AM, Yu KF, Zhang J, Toporsian M, Karumanchi SA, Levine RJ. Circulating anti-angiogenic factors during hypertensive pregnancy and increased risk of respiratory distress syndrome in preterm neonates.J Matern Fetal Neonatal Med 2012; 25(8):1447-52.
20. Young B, Levine RJ, Salahuddin S, Qian C, Lim KH, Karumanchi SA, Rana S. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 2010;23:366-370.
21. Srinivas SK, Larkin J, Sammel MD, Appleby D, Bastek J, Andrela CM, Ofori E, Elovitz MA. The use of angiogenic factors in discriminating preeclampsia: are they ready for prime time? J Matern Fetal Neonatal Med 2010;23:1294-1300.
22. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011;24:1187-1207.
23. Rana S, Hacker MR, Modest AM, Salahuddin S, Lim KH, Verlohren S, Perschel FH, Karumanchi SA. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125(7):911-9.
24. von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton Pipkin F, Cote AM, Douglas MJ, et al.; PIERS Study Group. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 2011;377:219-227.
25. Reddy UM, Bettegowda VR, Dias T, Yamada-Kushnir T, Ko CW, Willinger M. Term pregnancy: a period of heterogeneous risk for infant mortality. Obstet Gynecol 2011;117:1279-1287.
26. Fleischman AR, Oinuma M, Clark SL. Rethinking the definition of "term pregnancy". Obstet Gynecol 2010;116:136-139.
27. Ganzevoort W, Rep A, de Vries JI, Bonsel GJ, Wolf H; PETRAinvestigators. Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. Am J Obstet Gynecol 2006;195:495-503. (Pubitemid 44142383)
28. Martin JN Jr, Rinehart BK, May WL, Magann EF, Terrone DA, Blake PG. The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obstet Gynecol 1999;180:1373-1384. (Pubitemid 29293255)
29. Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsiaeclampsia. Am J Obstet Gynecol 2009;200:e481-487.
30. Stella CL, Sibai BM. Preeclampsia: diagnosis and management of the atypical presentation. J Matern Fetal Neonatal Med 2006;19:381-386. (Pubitemid 44272911)